Bispecific antibody prevents SARS-CoV-2 escape and protects mice from disease
Summary
Neutralizing antibodies targeting the receptor binding domain (RBD) of the SARS-CoV-2 Spike (S) are among the most promising approaches against coronavirus disease 2019 (COVID-19)1,2. We developed a bispecific, IgG1-like molecule based on two antibodies derived from COVID-19 convalescent donors, C121 and C1353. CoV-X2 simultaneously binds two independent sites on the RBD and, unlike its parental antibodies, completely prevents S binding to Angiotensin-Converting Enzyme 2 (ACE2), the virus cellular receptor. Furthermore, CoV-X2 recognizes a broad panel of RBD variants and neutralizes SARS-CoV-2 and the escape mutants generated by the single monoclonals at sub-nanomolar concentrations. In a novel model of SARS-CoV-2 infection with lung inflammation, CoV-X2 protects mice from disease and suppresses viral escape. Thus, simultaneous targeting of non-overlapping RBD epitopes by IgG-like bispecific antibodies is feasible and effective, combining into a single molecule the advantages of antibody cocktails.
Competing Interest Statement
In connection with this work the Institute for Research in Biomedicine has filed a provisional patent application on which L.V. is inventor (PCT/EP2020/085342). The Rockefeller University has filed a provisional patent application on which D.F.R. and M.C.N. are inventors.
Subject Area
- Biochemistry (13169)
- Bioengineering (10016)
- Bioinformatics (32066)
- Biophysics (16528)
- Cancer Biology (13608)
- Cell Biology (19340)
- Clinical Trials (138)
- Developmental Biology (10455)
- Ecology (15515)
- Epidemiology (2067)
- Evolutionary Biology (19808)
- Genetics (13105)
- Genomics (18141)
- Immunology (13254)
- Microbiology (31003)
- Molecular Biology (12915)
- Neuroscience (67710)
- Paleontology (496)
- Pathology (2089)
- Pharmacology and Toxicology (3615)
- Physiology (5637)
- Plant Biology (11623)
- Synthetic Biology (3241)
- Systems Biology (7930)
- Zoology (1794)